Given that VprBP‐mediated H2AT120p plays a causal role in tumorigenesis, we also have identified a small‐molecule inhibitor, named B32B3, capable of inhibiting VprBP kinase activity and tumor growth, even causing some partial tumor regression, in prostate xenograft models [11]. This evidence concerns the gene DCAF1 and neoplasm.